Antihypertensive effect of the mineralocorticoid receptor antagonist eplerenone: a pooled analysis of patient-level data from comparative trials using regulatory-approved doses

Antihypertensive effect of the mineralocorticoid receptor antagonist eplerenone: a pooled analysis of patient-level data from comparative trials using regulatory-approved doses

Mireille Fernet,1 Bruce Beckerman,2 Paula Abreu,2 Katharina Lins,3 John Vincent,2 Ellen Burgess4 1Department of Medical Affairs, Pfizer Canada Inc., Kirkland, QC, Canada; 2Department of Clinical Affairs, Pfizer Inc., New York, NY, USA; 3Department of Medical Affairs, Pfizer Ltd., Tadworth,...

Full description

Bibliographic Details
Main Authors: Fernet M, Beckerman B, Abreu P, Lins K, Vincent J, Burgess E
Format: Article
Language:English
Published: Dove Medical Press 2018-09-01
Series:Vascular Health and Risk Management
Subjects:
Hypertension
Eplerenone
aldosterone
cardiovascular
selective mineralocorticoid blocker.
Online Access:https://www.dovepress.com/antihypertensive-effect-of-the-mineralocorticoid-receptor-antagonist-e-peer-reviewed-article-VHRM

Internet

https://www.dovepress.com/antihypertensive-effect-of-the-mineralocorticoid-receptor-antagonist-e-peer-reviewed-article-VHRM

Similar Items